Cellectis

Roughly every 3 minutes, someone in the United States is diagnosed with blood cancer.   This Blood Cancer Awareness Month, we're joining the call to share information about warning signs & global efforts to fight blood cancer.   Let’s raise awareness of this devastating disease and the impact it has on patients.   #BloodCancerAwarenessMonth #BloodCancer #CellTherapy #GeneTherapy

Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety. To read the press release: https://lnkd.in/gKr42m2u #celltherapy #genetherapy

Does it make sense to treat solid tumors with CAR T-cells?   While CAR T-cell therapy has been successful for some cancers, it faces challenges in treating solid tumors.   Two main obstacles are: 🚫The tumor micro-environment (TME), including Cancer-associated fibroblasts (CAFs), which hinder T-cell effectiveness. 🚫Lack of tumor-specific antigens, leading to potential harm to healthy tissues, raising safety concerns.   A proposed solution:  Using TALEN® gene editing technology to design a dual CAR T-cell with: ✅ A main CAR targeting CAFs ✅An inducible CAR activated only after CAFs recognition, targeting tumor-associated antigens named mesothelin.   The results: The SMART Dual CAR T-cells efficiently infiltrate and target solid tumors in physiologically relevant mice models, with no observable off-tumor toxicity.   This approach showed promising results in breast cancer mouse models, effectively targeting tumors without harming healthy tissues. This strategy could potentially overcome key challenges in using CAR T-cell therapy for solid tumors.   Here is the link to access the full study: https://lnkd.in/eDpn_qpc ♻ Share if you liked this idea. Thoughts? Drop them in the comments ⤵

Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors. To read the press release: https://lnkd.in/e-U_JD6D #celltherapy #cancer

Graft-versus-Host Disease (GvHD): a key consideration in allogeneic cell therapies?   In the world of allogeneic CAR T-cell therapies, Graft-versus-Host Disease (GvHD) is our double-edged sword.   Imagine these powerful T-cells as elite mercenaries, hired to eliminate a dangerous threat - cancer.   They're incredibly effective, but there's a catch: they're foreigners in your body's landscape.   Like a mercenary force that can't distinguish between civilians and enemies, these T-cells may mistakenly attack healthy tissues, leading to GvHD.   GvHD occurs when donor immune cells recognize the recipient's tissues as foreign and attack them. This can be a serious complication in treatments using donor-derived cells.   Allogeneic CAR T cell therapies are engineered to minimize GvHD risk.   Recent advancements have dramatically reduced this risk: For example, disruption of the T-cell receptor alpha constant (TRAC) gene minimizes risk of GvHD. Current data suggests that the GvHD risk in allogeneic CAR T-cell therapy is much lower than initially feared: A study (link at the end) involved the use of an allogeneic CAR T-cell product demonstrated a manageable safety profile with no clinically significant GvHD observed. Specifically, only 2 out of the 25 patients involved in the study developed grade 1 acute cutaneous GvHD, indicating a low incidence of GvHD in the trial. While allogeneic CAR T-cell therapy still carries a risk of GvHD, ongoing research and technological advancements are making it an increasingly safe option, potentially offering the benefits of "off-the-shelf" availability without significantly compromising patient safety. What are your thoughts on the future of allogeneic CAR T-cell therapies in minimizing GvHD? Drop them in the comments ⤵ https://lnkd.in/ebzkVm4i #celltherapy #genetherapy #cancer

Cellectis appoints Dr. Adrian Kilcoyne MD MPH MBA as Chief Medical Officer. To read the press release: https://lnkd.in/gnxQAZNS #celltherapy #genetherapy

Cellectis Provides Financial Results for the Second Quarter 2024. Full press release available here: https://lnkd.in/eF4gB3qV #celltherapy, #geneediting, #allogeneic

FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment. Full press release here: https://lnkd.in/esEkSr7P #allogeneic, #celltherapy, #genetherapy

FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment. Full press release available here: https://lnkd.in/g6Y5pNnE #allogeneic, #celltherapy, #genetherapy

When T-Cells Fail: The Struggle Against Cancer 🔍   T-cells are a key component of the body's natural defense against cancer.   But in this gripping video, we observe T-cells trying and failing to attack cancer cells. Despite their best efforts, the T-cells are outmatched. Tumors have evolved cunning ways to escape T-cell mediated killing. They've developed mechanisms to evade detection, such as downregulating tumor antigens or releasing immunosuppressive factors. This allows cancers to grow unchecked by the immune system.   Exhausted, the T-cells are forced to retreat, losing their ability to effectively kill cancer cells.   Harnessing and enhancing the anti-tumor activity of T-cells is a major focus of cancer immunotherapy research and treatment.   Immunotherapy works by blocking the inhibitory signals that cancer cells use to suppress T-cell activity, thereby reinvigorating the T-cell response against the tumor.   What do you think is the most promising approach to cancer immunotherapy? Share your thoughts below ⤵ Thanks to the team at Nanolive SA for sharing this video, which was captured label-free using a Nanolive holotomographic microscope. #cancer #celltherapy